Drugs / AV-1959R
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06831812 | Jun 2024 → Dec 2025 | Alzheimer disease | Nuravax, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AV-1959R | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06831812 ↗ |
| Modality | Vaccine | “AV-1959R is an investigational adjuvanted vaccine designed to induce a targeted immune response against beta-amyloid (Aβ)” NCT06831812 ↗ |